Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV positive after voluntary counselling and testing~* Aged between 18 and 60 years of age~* Antiretroviral treatment naive~* CD4+ cell count of \<200 cells/mm3 at the time of TB diagnosis~* ALT \<5 times ULN~* Serum creatinine \<1.4 mg/dl~* Haemoglobin \>8 mg/L~* TB diagnosis; either probable (clinical symptoms plus chest x-ray and response to anti-TB medication) or definitive( sputum AFB culture confirmed) and receiving or planning to receive rifampicin-containing anti-TB therapy for at least a 2 week period before the initiation of ART~* No other active OI (CDC class C event)~* Able to provide written informed consent~Exclusion Criteria:~* Current use of steroids and other immunosuppressive agents~* Current use of any prohibited medications related to compliance and drug pharmacokinetics~* Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial.~* Previous exposure to nevirapine monotherapy~* Unlikely to be able to remain in follow-up for the protocol defined period~* Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST \< 5 x ULN.~* Karnofsky performance score \<30%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): IDV/r 600/100 mg + rifampicin

Based on this trial design, predict the completion outcome and termination type (if applicable).